Results 31 to 40 of about 2,398,808 (296)

Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis. [PDF]

open access: yes, 2012
OBJECTIVE: To estimate the cost effectiveness of vaccinating people with high risk conditions against invasive pneumococcal disease using the 13 valent pneumococcal conjugate vaccine.
Edmunds, W. John   +14 more
core   +2 more sources

Additional file 2 of An amino acid transporter subunit as an antibody–drug conjugate target in colorectal cancer

open access: yes, 2023
Additional file 2: Supplementary Fig. 2. A) Internalization of the anti-CD98hcECTO antibody in SW480 cells, analyzed by immunofluorescence. Scale bar = 25 μm.
Pandiella, Atanasio   +15 more
core   +1 more source

Novel method for screening functional antibody with comprehensive analysis of its immunoliposome

open access: yesScientific Reports, 2021
Development of monoclonal antibody is critical for targeted drug delivery because its characteristics determine improved therapeutic efficacy and reduced side-effect.
Shusei Hamamichi   +4 more
doaj   +1 more source

Toward Homogenous Antibody Drug Conjugates Using Enzyme-Based Conjugation Approaches

open access: yesPharmaceuticals, 2021
In the last few decades, antibody-based diagnostic and therapeutic applications have been well established in medicine and have revolutionized cancer managements by improving tumor detection and treatment.
Ahmad Fawzi Hussain   +8 more
doaj   +1 more source

Antibody–Drug Conjugates for Cancer Therapy [PDF]

open access: yesMolecules, 2020
Antibody–drug conjugates (ADCs) are novel drugs that exploit the specificity of a monoclonal antibody (mAb) to reach target antigens expressed on cancer cells for the delivery of a potent cytotoxic payload. ADCs provide a unique opportunity to deliver drugs to tumor cells while minimizing toxicity to normal tissue, achieving wider therapeutic windows ...
Umbreen Hafeez   +3 more
openaire   +4 more sources

Trastuzumab deruxtecan: A quantum leap in HER2-positive breast cancer

open access: yesIndian Journal of Medical and Paediatric Oncology, 2019
Docetaxel, trastuzumab, and pertuzumab, known as THP, is the preferred first-line treatment for HER2-positive advanced breast cancer, and the second-line drug of choice is trastuzumab emtansine.
Manikandan Dhanushkodi
doaj   +1 more source

HER2-targeting Peptide Drug Conjugate with Better Penetrability for Effective Breast Cancer Therapy

open access: yesBIO Integration, 2023
Antibody-drug conjugates (ADCs) have the following advantages: target specificity; wide therapeutic index; and prolonged circulation half-life. A key limitation of ADCs, however, is the large size (~150 kDa), which markedly slows diffusion through the ...
Yixia Liang   +9 more
doaj   +1 more source

EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma [PDF]

open access: yes, 2010
PURPOSE: EphA2 overexpression is frequently observed in endometrial cancers and is predictive of poor clinical outcome. Here, we use an antibody drug conjugate (MEDI-547) composed of a fully human monoclonal antibody against both human and murine EphA2 ...
남은지
core   +1 more source

Characterization and in vitro data of antibody drug conjugates (ADCs) derived from heterotrifunctional linker designed for the site-specific preparation of dual ADCs

open access: yesData in Brief, 2018
Experimental procedures and 1H and 13C NMR of the heterotrifunctional linker used for preparation of dual drug conjugates and PBD payload are included.
Amit Kumar   +7 more
doaj   +1 more source

Antibody-drug conjugates

open access: yesPractical oncology, 2023
This article is a literature review of the available data on the history of origin, mechanism of action, and the main currently available conjugate-linked monoclonal antibodies. The use of conjugate-linked monoclonal antibodies in the therapy of both solid and hematological malignancies is a promising direction of anti-tumor therapy.
E.O. Stepanova   +2 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy